The US Army Institute of Surgical Research (USAISR), located at Fort Sam Houston, Texas, has developed several anti-MRSA formulations that significantly reduce biofilm viability in vitro. These formulations target biofilm viability and structural integrity.
The USAISR is seeking a potential qualified contractor to conduct a study using a clinically relevant animal model to identify the most effective, peptide-based treatments selected from in vitro screening for controlling methicillin-resistant S. aureus (MRSA) biofilm infections in wounds to improve wound outcomes.
Further details are available under Solicitation Number: W81XWH-14-0-KSLW. The response deadline is September 12, 2014.